| Item Type | Name |
|
Concept
|
Pyrazoles
|
|
Academic Article
|
Ibrutinib Monotherapy in Symptomatic, Treatment-Na?ve Patients With Waldenstr?m Macroglobulinemia.
|
|
Academic Article
|
CXCR4 mutations affect presentation and outcomes in patients with Waldenstr?m macroglobulinemia: A systematic review.
|
|
Academic Article
|
Natural history of Waldenstr?m macroglobulinemia following acquired resistance to ibrutinib monotherapy.
|
|
Academic Article
|
Ibrutinib penetrates the blood brain barrier and shows efficacy in the therapy of Bing Neel syndrome.
|
|
Academic Article
|
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study.
|
|
Academic Article
|
CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstr?m macroglobulinaemia treated with ibrutinib.
|
|
Academic Article
|
Low risk of Pneumocystis jirovecii pneumonia and invasive aspergillosis in patients with Waldenstr?m macroglobulinaemia on ibrutinib.
|
|
Academic Article
|
PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies.
|
|
Academic Article
|
CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr?m macroglobulinaemia cells.
|
|
Academic Article
|
HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.
|
|
Academic Article
|
How to Sequence Therapies in Waldenstr?m Macroglobulinemia.
|
|
Academic Article
|
Ibrutinib discontinuation in Waldenstr?m macroglobulinemia: Etiologies, outcomes, and IgM rebound.
|
|
Academic Article
|
How we manage Bing-Neel syndrome.
|
|
Academic Article
|
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr?m macroglobulinemia: the ASPEN study.
|
|
Academic Article
|
Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia.
|
|
Academic Article
|
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells.
|
|
Academic Article
|
Atrial fibrillation associated with ibrutinib in Waldenstr?m macroglobulinemia.
|
|
Academic Article
|
TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstr?m macroglobulinaemia.
|
|
Academic Article
|
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.
|
|
Academic Article
|
What is new in the treatment of Waldenstrom macroglobulinemia?
|
|
Academic Article
|
Ibrutinib withdrawal symptoms in patients with Waldenstr?m macroglobulinemia.
|
|
Academic Article
|
Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation.
|
|
Academic Article
|
Future therapeutic options for patients with Waldenstr?m macroglobulinemia.
|
|
Academic Article
|
Ibrutinib in previously treated Waldenstr?m's macroglobulinemia.
|
|
Academic Article
|
Ibrutinib and Rituximab in Waldenstr?m's Macroglobulinemia.
|
|
Academic Article
|
Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenstr?m macroglobulinemia.
|
|
Academic Article
|
Biology, prognosis, and therapy of Waldenstr?m Macroglobulinemia.
|
|
Academic Article
|
Ibrutinib for patients with rituximab-refractory Waldenstr?m's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
|
|
Academic Article
|
Genomics, Signaling, and Treatment of Waldenstr?m Macroglobulinemia.
|
|
Academic Article
|
Bruton tyrosine kinase inhibitors in the management of Waldenstr?m macroglobulinemia.
|
|
Academic Article
|
Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstr?m macroglobulinemia.
|